Gene Logic, Organon Ink Repurposing Pact

Gene Logic, Inc. and Organon have entered into a drug repositioning agreement to seek alternative development paths for multiple drug candidates of which Organon previously discontinued clinical development.

Under the terms of the agreement, Gene Logic will seek new therapeutic uses for Organon compounds. Upon discovery of potential new therapeutic utility, both companies will become equal owners and may decide to jointly develop and commercialize the drug candidate. Gene Logic will receive a success-based milestone payment for each therapeutic candidate that Organon selects to develop.

David Nicholson, executive vice president of Global R&D at Organon said, “We believe Gene Logic’s program has the potential to find new value in our previously low priority drug candidates. Organon continues to seek new technologies to increase our drug research output. This technology is an opportunity to address that.”

Louis Tartaglia, Ph.D., general manager and senior vice president of drug repositioning for Gene Logic, said, “We believe that this agreement with Organon represents a significant opportunity for both parties. Gene Logic’s Drug Repositioning Program is designed to provide a comprehensive picture of the drug candidates’ biological activities and determine if there are new therapeutic uses for these potential medicines. Finding new therapeutic uses for low priority drug candidates of Organon would benefit both companies and bring new medicines to patients.”